VITEK® 2 GN ID CARD
Received Dec 28, 2016
Report 1950204-2016-00213 · MDR key 6208565
Device
Product problems
- Incorrect Or Inadequate Test Results
- Incorrect Or Inadequate Test Results
Patient
Not reported
- No Patient Involvement
- No Patient Involvement
Narrative
Additional Manufacturer Narrative
A BIOMÉRIEUX INTERNAL INVESTIGATION WAS CONDUCTED ON A API SURVEY ORGANISM (API PROFICIENCY URINE UR-11). THE ORGANISM WAS TESTED ON MULTIPLE LOTS OF GN CARDS IN DUPLICATE, INCLUDING 4 LOTS REPORTED BY CUSTOMERS AND 1 RANDOM GN LOT. THE API 20 E WAS PERFORMED, AS WAS THE VITEK® MS. ON 2 OF THE CUSTOMER LOTS, A LOW DISCRIMINATION CALL OF P. PENNERI / P. HAUSERI WAS OBTAINED. ON THE REMAINING 2 CUSTOMER LOTS TESTED AND THE RANDOM LOT, A LOW DISCRIMINATION CALL OF P. PENNERI / P. PNEUMOTROPICA WAS OBTAINED. API 20 E GAVE A GOOD IDENTIFICATION CALL OF P. VULGARIS GROUP. VITEK® MS GAVE A LOW DISCRIMINATION CALL OF P. PENNERI / P. VULGARIS. SINCE THE ORGANISM IS INDOLE POSITIVE, THE VITEK® MS CALL OF P. VULGARIS WOULD BE CORRECT. A COMPARISON OF REACTION RESULTS FOR CARDS GIVING THE MISIDENTIFICATION CALL OF P. PENNERI / P. HAUSERI AGAINST THE EXPECTED REACTION RESULTS FOR P. VULGARIS REVEALED 3 ATYPICAL NEGATIVE REACTIONS (PLE, ILATK, AGLU). A COMPARISON OF REACTION RESULTS FOR CARDS GIVING THE MISIDENTIFICATION CALL OF P. PENNERI/P. PNEUMOTROPICA AGAINST THE EXPECTED REACTION RESULTS FOR P. VULGARIS REVEALED 4 ATYPICAL NEGATIVE REACTIONS (PROA, PLE, ILATK, AGLU). THE INVESTIGATION CONCLUDED THE SUBMITTED ISOLATE EXHIBITS ATYPICAL GROWTH BEHAVIOR. THE VITEK® 2 GN TEST KIT PERFORMED AS INTENDED. .
Description of Event or Problem
A CUSTOMER IN THE UNITED STATES REPORTED TO BIOMÉRIEUX A MISIDENTIFICATION API PROFICIENCY SURVEY, AS PROTEUS HAUSERI 96%, IN ASSOCIATION WITH THE VITEK® 2 GN CARD. THE SAMPLE WAS PLATED AND SUBBED TWICE BEFORE SET-UP. IDENTIFICATION WAS NOT REPEATED ON VITEK® 2. THERE IS NO INDICATION OR REPORT FROM THE CUSTOMER THAT THE DISCREPANT RESULT LED TO ANY ADVERSE EVENT RELATED TO A PATIENT'S STATE OF HEALTH. AN INTERNAL BIOMÉRIEUX INVESTIGATION HAS BEEN INITIATED.